Made possible by the financial support of AbbVie

GnRHa Treatment for Central Precocious Puberty Linked to Transient Weight Gain

An observational study from Portugal indicates GnRHa therapy as a treatment for central precocious puberty was associated with an increase in body weight that subsided 1 year after treatment cessation.

Study Details Differences in Diagnosis, Characteristics of Precocious Puberty During Pandemic

Data from a cross-sectional study from a children's hospital in Shanghai details the increased rate of diagnosis and differences in clinical features of girls diagnosed with precocious puberty during the pandemic against prepandemic periods.

Study Examines Link Between Increased Sedentary Time, Precocious Puberty Diagnoses in Italy

After previous studies found an increase in the diagnosis of central precocious puberty, investigators launched a new study to assess whether decreases in physical activity might be linked to the increased diagnosis rate.

Triptorelin-Stimulated LH Concentrations Can Help Diagnosis Central Precocious Puberty

A case-control study provides insight into the diagnostic utility of triptorelin-stimulated luteinizing hormone concentrations for diagnosis of central precocious puberty in girls.

Soy Consumption Has No Influence on Risk of Precocious Puberty, Early Menarche

A systematic review and meta-analysis provide insight into the risks of precocious puberty and early menarche based on consumption of a soy-based infant diet.

Pelvic Ultrasonography Provides Low-Cost, Noninvasive Tool for Diagnosing Precocious Puberty

A recent systematic review and meta-analysis provide a deep dive into the effectiveness of pelvic ultrasonography as a complementary tool to GnRH testing for differentiating between precocious puberty and premature thelarche.

Study Assesses Brain Volume Differences in Girls with Central Precocious Puberty

An imaging study of girls with idiopathic CPP and matched controls suggests idiopathic CPP was associated with increased gray matter and white matter volumes in the cerebral area.

GnRHa Not Associated with Increased PCOS Risk in Patients with Endocrine Disorders

Using data from more than 50 women, investigators determined exposure to GnRHa treatment was not associated with an increased risk of developing PCOS in women with CPP treated with GnRHa.

Study Details Prevalence of Genetic Variants in Central Precocious Puberty

Results of a recent study provide insight into the prevalence of rare sequence variants among the MKRN3, DLK1, KISS1, and KISS1R genes in children with CPP.

Study Details Factors Negatively Impacting Time to Menarche in Central Precocious Puberty

Mount Sinai-led chart review provides insight into the influence of various factors on time to menarche among girls with central precocious puberty who received GnRHa treatment.

Risk Score Model Could Provide Inexpensive CPP Diagnosis Tool

A cross-sectional study has returned results that suggest a risk score model could help identify patients with central precocious puberty without the need for more expensive and invasive stimulation tests.

Influence of GnRHa on Long-Term Outcomes in Idiopathic Central Precocious Puberty

A systematic review and meta-analysis detail the effects of GnRHa therapy on final adult height, BMI, risk of PCOS, and more long-term outcomes among patients with idiopathic CPP.

Erica Eugster, MD, provides an overview of disease management of central precocious puberty.

Experts from the Mayo Clinic offer insight into the causes, forms, risk factors, and management of precocious puberty.

Experts from the Mayo Clinic offer insight into the causes, forms, risk factors, and management of precocious puberty.

The National Organization for Rare Diseases summarizes available information related to diagnosis and management of precocious puberty as well as providing links to relevant organization and recent journal articles related to precocious puberty.

Experts from Stanford Children’s Health and Lucile Packard Children’s Hospital detail patient-focused data and information for the management of precocious puberty.

Riley Children’s Health provides an overview of key points related to precocious puberty, including links to support services and resources for patients and providers.

AbbVie is pleased to present this program titled “Recognizing the Signs of Central Precocious Puberty (CPP) Earlier: Journey From Patient to Referral Through Case Studies”. This program was originally presented at the annual American Academy of Pediatrics (AAP) National Conference and Exhibition in Orlando, Florida. We will be hearing from Karen Oerter Klein, MD who will review the signs of CPP and demonstrate importance of early detection. This presentation will include 3 case studies to reinforce the importance of early diagnosis and referring your patient.

Recognizing Pubertal Onset & Clues on When to Refer for Possible Central Precocious Puberty

Potential Psychosocial Issues Associated with CPP

Clues to Unraveling the Mystery of Central Precocious Puberty

What Is the Pediatrician’s Role?